



**Interface Prescribing  
& New Therapies Subgroup**



**May 2013**

**Eflornithine 11.5% cream**

**The New Therapies Subgroup discussed the above drug at a meeting on the 17<sup>th</sup> July 2007 and again in May 2013. The recommendation of this subgroup is as follows:\***

The New Therapies Subgroup of the GMMMG considered the therapeutic use of eflornithine 11.5% cream (Vaniqa<sup>®</sup>) for the treatment of facial hirsutism in women.

**The group recommends the use of eflornithine 11.5% cream for the treatment of female facial hirsutism only in patients with a confirmed diagnosis of an androgenic disease and in whom treatment with co-cyprindiol is ineffective, contraindicated, or considered inappropriate.**

**Eflornithine 11.5% cream may offer advantages over existing therapy for some women as it avoids the risks associated with systemic therapies.**

According to set criteria eflornithine was deemed to be a lower priority for funding

**Review Date May 2018.**

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.  
\$To be read in conjunction with the SPC.